Zacks: Analysts Anticipate AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Will Announce Quarterly Sales of $25.60 Million

Brokerages expect AVEO Pharmaceuticals, Inc. (NASDAQ:AVEOGet Rating) to report $25.60 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for AVEO Pharmaceuticals’ earnings. The lowest sales estimate is $24.95 million and the highest is $26.04 million. AVEO Pharmaceuticals reported sales of $7.56 million in the same quarter last year, which suggests a positive year-over-year growth rate of 238.6%. The business is expected to announce its next earnings report on Monday, January 1st.

On average, analysts expect that AVEO Pharmaceuticals will report full year sales of $115.93 million for the current fiscal year, with estimates ranging from $112.00 million to $122.89 million. For the next year, analysts expect that the firm will report sales of $176.64 million, with estimates ranging from $164.50 million to $200.74 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that follow AVEO Pharmaceuticals.

AVEO Pharmaceuticals (NASDAQ:AVEOGet Rating) last released its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.04). The business had revenue of $20.92 million during the quarter, compared to the consensus estimate of $21.33 million. AVEO Pharmaceuticals had a negative net margin of 67.57% and a negative return on equity of 90.63%. During the same period last year, the company posted ($0.72) earnings per share.

A number of brokerages have weighed in on AVEO. Jonestrading began coverage on shares of AVEO Pharmaceuticals in a research note on Monday, March 14th. They set a “buy” rating for the company. Zacks Investment Research upgraded shares of AVEO Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, March 17th. Finally, StockNews.com began coverage on shares of AVEO Pharmaceuticals in a research note on Thursday, March 31st. They set a “hold” rating for the company. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, AVEO Pharmaceuticals has an average rating of “Buy” and a consensus target price of $18.50.

AVEO stock opened at $4.50 on Monday. The stock has a market capitalization of $155.15 million, a PE ratio of -3.72 and a beta of 1.19. AVEO Pharmaceuticals has a 12-month low of $3.06 and a 12-month high of $7.59. The company has a current ratio of 4.81, a quick ratio of 4.73 and a debt-to-equity ratio of 1.03. The stock’s 50 day simple moving average is $4.86 and its 200 day simple moving average is $4.66.

Several large investors have recently bought and sold shares of AVEO. Lazard Asset Management LLC purchased a new stake in shares of AVEO Pharmaceuticals in the 4th quarter worth $35,000. PDT Partners LLC purchased a new stake in shares of AVEO Pharmaceuticals in the 1st quarter worth $61,000. Shay Capital LLC purchased a new stake in shares of AVEO Pharmaceuticals in the 4th quarter worth $62,000. Dakota Wealth Management purchased a new stake in shares of AVEO Pharmaceuticals in the 1st quarter worth $70,000. Finally, D. E. Shaw & Co. Inc. purchased a new stake in shares of AVEO Pharmaceuticals in the 4th quarter worth $184,000. Hedge funds and other institutional investors own 52.61% of the company’s stock.

About AVEO Pharmaceuticals (Get Rating)

AVEO Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the treatment of RCC, HCC, immunologically cold tumors, and CCA.

Featured Articles

Get a free copy of the Zacks research report on AVEO Pharmaceuticals (AVEO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AVEO Pharmaceuticals (NASDAQ:AVEO)

Want More Great Investing Ideas?

Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.